PDS Biotechnology Regains Nasdaq Compliance After Minimum Bid Price Deficiency
核心洞察
PDS Biotechnology received a Nasdaq deficiency notice on February 25, 2026, after its stock traded below the $1.00 minimum bid price for 30 consecutive business days.
The company successfully regained compliance with Nasdaq Listing Rule 5550(a)(2), with Nasdaq confirming the matter closed on June 2, 2026.
The compliance restoration removes the immediate threat of delisting from the Nasdaq Capital Market, where the stock continues to trade under ticker PDSB.
PDS Biotechnology has successfully regained compliance with Nasdaq's minimum bid price requirement, removing the immediate threat to its continued listing on the Nasdaq Capital Market, according to company disclosures.
The company disclosed on February 25, 2026, that it had received a deficiency letter from Nasdaq after its common stock had traded below the $1.00 minimum bid price for 30 consecutive business days, placing its listing status at risk under Listing Rule 5550(a)(2).
On June 2, 2026, PDS Biotechnology reported that Nasdaq had notified the company in writing that it had regained compliance with the minimum bid price requirement, formally closing the matter and removing the immediate threat to its listing status. The company's stock continues to trade on Nasdaq under the ticker symbol PDSB.
Subsequent Compliance Challenge
In a separate development, PDS Biotechnology received another Nasdaq deficiency notice on July 30, 2026, for again failing to maintain the $1.00 minimum bid price under Listing Rule 5550(a)(2) for 30 consecutive business days. Under Nasdaq rules, the company has 180 days, until January 26, 2027, to regain compliance and may be eligible for an additional 180-day compliance period. Options to regain compliance may include a reverse stock split.
The company disclosed this latest deficiency in an 8-K filing dated July 31, 2026, confirming that its stock continues to trade on the Nasdaq Capital Market during the compliance period.